145 related articles for article (PubMed ID: 21269615)
1. Effect of GnRH agonist and hCG treatment on VEGF, angiopoietin-2, and VE-cadherin: trying to explain the link to ovarian hyperstimulation syndrome.
Cerrillo M; Pacheco A; Rodríguez S; Gómez R; Delgado F; Pellicer A; Garcia-Velasco JA
Fertil Steril; 2011 Jun; 95(8):2517-9. PubMed ID: 21269615
[TBL] [Abstract][Full Text] [Related]
2. GnRH Agonist Triggering Modulates PEDF to VEGF Ratio Inversely to hCG in Granulosa Cells.
Miller I; Chuderland D; Ron-El R; Shalgi R; Ben-Ami I
J Clin Endocrinol Metab; 2015 Nov; 100(11):E1428-36. PubMed ID: 26308290
[TBL] [Abstract][Full Text] [Related]
3. Serum inhibin A, VEGF and TNFalpha levels after triggering oocyte maturation with GnRH agonist compared with HCG in women with polycystic ovaries undergoing IVF treatment: a prospective randomized trial.
Babayof R; Margalioth EJ; Huleihel M; Amash A; Zylber-Haran E; Gal M; Brooks B; Mimoni T; Eldar-Geva T
Hum Reprod; 2006 May; 21(5):1260-5. PubMed ID: 16439507
[TBL] [Abstract][Full Text] [Related]
4. Differential regulation of VEGF after final oocyte maturation with GnRH agonist versus hCG: a rationale for OHSS reduction.
Cerrillo M; Rodríguez S; Mayoral M; Pacheco A; Martínez-Salazar J; Garcia-Velasco JA
Fertil Steril; 2009 Apr; 91(4 Suppl):1526-8. PubMed ID: 18990367
[TBL] [Abstract][Full Text] [Related]
5. Administration of a gonadotropin-releasing hormone agonist affects corpus luteum vascular stability and development and induces luteal apoptosis in a rat model of ovarian hyperstimulation syndrome.
Scotti L; Irusta G; Abramovich D; Tesone M; Parborell F
Mol Cell Endocrinol; 2011 Mar; 335(2):116-25. PubMed ID: 21238536
[TBL] [Abstract][Full Text] [Related]
6. Effects of gonadotropin-releasing hormone antagonists on the expression of vascular endothelial growth factor and its receptors in a rat model of ovarian hyperstimulation syndrome.
Tong XM; Zhang SY; Song T; Xu WH; Lin XN; Shu J; Liu L
Chin Med J (Engl); 2008 Dec; 121(23):2434-9. PubMed ID: 19102964
[TBL] [Abstract][Full Text] [Related]
7. Agonist trigger: what is the best approach? Agonist trigger and low dose hCG.
Humaidan P
Fertil Steril; 2012 Mar; 97(3):529-30. PubMed ID: 22154368
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of low dose hCG for luteal support after triggering ovulation with a GnRH agonist in cases of polyfollicular development.
Krause BT; Ohlinger R
Eur J Obstet Gynecol Reprod Biol; 2006 May; 126(1):87-92. PubMed ID: 16377065
[TBL] [Abstract][Full Text] [Related]
9. Standard human chorionic gonadotropin versus double trigger for final oocyte maturation results in different granulosa cells gene expressions: a pilot study.
Haas J; Ophir L; Barzilay E; Machtinger R; Yung Y; Orvieto R; Hourvitz A
Fertil Steril; 2016 Sep; 106(3):653-659.e1. PubMed ID: 27341989
[TBL] [Abstract][Full Text] [Related]
10. Comparison of gene expression profiles in granulosa and cumulus cells after ovulation induction with either human chorionic gonadotropin or a gonadotropin-releasing hormone agonist trigger.
Borgbo T; Povlsen BB; Andersen CY; Borup R; Humaidan P; Grøndahl ML
Fertil Steril; 2013 Oct; 100(4):994-1001. PubMed ID: 23856575
[TBL] [Abstract][Full Text] [Related]
11. No room for cancellation, coasting, or ovarian hyperstimulation syndrome in oocyte donation cycles.
Hernández ER; Gómez-Palomares JL; Ricciarelli E
Fertil Steril; 2009 Apr; 91(4 Suppl):1358-61. PubMed ID: 18555236
[TBL] [Abstract][Full Text] [Related]
12. Physiology and pathology of ovarian hyperstimulation syndrome.
Gómez R; Soares SR; Busso C; Garcia-Velasco JA; Simón C; Pellicer A
Semin Reprod Med; 2010 Nov; 28(6):448-57. PubMed ID: 21082502
[TBL] [Abstract][Full Text] [Related]
13. Comparison of "triggers" using leuprolide acetate alone or in combination with low-dose human chorionic gonadotropin.
Shapiro BS; Daneshmand ST; Garner FC; Aguirre M; Hudson C
Fertil Steril; 2011 Jun; 95(8):2715-7. PubMed ID: 21550042
[TBL] [Abstract][Full Text] [Related]
14. GnRHa to trigger final oocyte maturation: a time to reconsider.
Humaidan P; Papanikolaou EG; Tarlatzis BC
Hum Reprod; 2009 Oct; 24(10):2389-94. PubMed ID: 19608565
[TBL] [Abstract][Full Text] [Related]
15. Short coasting of 1 or 2 days by withholding both gonadotropins and gonadotropin-releasing hormone agonist prevents ovarian hyperstimulation syndrome without compromising the outcome.
Moon HS; Joo BS; Moon SE; Lee SK; Kim KS; Koo JS
Fertil Steril; 2008 Dec; 90(6):2172-8. PubMed ID: 18439601
[TBL] [Abstract][Full Text] [Related]
16. Vascular endothelial growth factor and basic fibroblast growth factor in polycystic ovary syndrome during controlled ovarian hyperstimulation.
Artini PG; Monti M; Matteucci C; Valentino V; Cristello F; Genazzani AR
Gynecol Endocrinol; 2006 Aug; 22(8):465-70. PubMed ID: 17012110
[TBL] [Abstract][Full Text] [Related]
17. Low-dose human chorionic gonadotropin versus estradiol/progesterone luteal phase support in gonadotropin-releasing hormone agonist-triggered assisted reproductive technique cycles: understanding a new approach.
Garcia-Velasco JA; Motta L; López A; Mayoral M; Cerrillo M; Pacheco A
Fertil Steril; 2010 Dec; 94(7):2820-3. PubMed ID: 20673892
[TBL] [Abstract][Full Text] [Related]
18. Gonadotropin-releasing hormone agonist combined with a reduced dose of human chorionic gonadotropin for final oocyte maturation in fresh autologous cycles of in vitro fertilization.
Shapiro BS; Daneshmand ST; Garner FC; Aguirre M; Thomas S
Fertil Steril; 2008 Jul; 90(1):231-3. PubMed ID: 17981269
[TBL] [Abstract][Full Text] [Related]
19. 1,500 IU human chorionic gonadotropin administered at oocyte retrieval rescues the luteal phase when gonadotropin-releasing hormone agonist is used for ovulation induction: a prospective, randomized, controlled study.
Humaidan P; Ejdrup Bredkjaer H; Westergaard LG; Yding Andersen C
Fertil Steril; 2010 Feb; 93(3):847-54. PubMed ID: 19200959
[TBL] [Abstract][Full Text] [Related]
20. GnRH agonist vs. hCG for triggering of ovulation--differential effects on gene expression in human granulosa cells.
Haas J; Ophir L; Barzilay E; Yerushalmi GM; Yung Y; Kedem A; Maman E; Hourvitz A
PLoS One; 2014; 9(3):e90359. PubMed ID: 24603682
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
